Currently, the five classes of therapies approved for PAH target the Ca2+ entry and the three main dysfunctional endothelial pathways: NO, prostacyclin, and endothelin-1 pathways [27,28]. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.